Medical News
Biosimilar Bevacizumab in Patients with Non-Small Cell Lung Cancer
Biosimilar drugs are essentially analogous to generics for biological medicines. The patent protection for the original bevacizumab product will expire in the European Union in 2022. Consequently, several companies have already embarked on developing a biosimilar molecule.
Position of Generic Drugs in Oncology: What Are Their Main Advantages?
Generics – as is well known – are products containing the same active substance as the original medicinal product, which can enter the market after the patent protection of the original drug has…
Monocyte Distribution Width as a New Indicator of Sepsis in High-Risk Patients
Most septic patients are first encountered in the emergency department, where sepsis detection is often delayed, partly due to a lack of effective biomarkers. The study presented below evaluated the…
New Hematological Biomarker for Early Diagnosis of Sepsis
Sepsis is one of the leading causes of mortality and healthcare expenditure worldwide. Early diagnosis and treatment of septic conditions improve patient prognosis. However, the initial symptoms of…
Interstitial Lung Processes and Their Fibrotic Progression
Interstitial lung processes (ILPs) include more than 200 clinical units that share diffuse involvement of lung tissue and thus have similar clinical, radiological, and functional findings. However,…
Evaluation of Continuity of Care in Patients with mCRC – Baseline Characteristics of Participants in the PROMETCO Study
During this year's World Congress of the European Society for Medical Oncology (ESMO) on gastrointestinal malignancies, the baseline characteristics of participants in the ongoing PROMETCO study, which...
Trifluridine/tipiracil in Real Clinical Practice – Current Data from Spain
Trifluridine/tipiracil is indicated for the treatment of patients with refractory metastatic colorectal cancer (mCRC), where clinical studies have shown it extends overall survival (OS) and progression-free...
Evaluation of Treatment Response in CLL
The size of lymph nodes, liver, spleen, blood cell counts, systemic symptoms... Changes in these indicators provide clear information on whether the disease of chronic lymphocytic leukemia (CLL) has progressed,...
Idiopathic Pulmonary Fibrosis: Can This Disease Be Named More Precisely?
Much about idiopathic pulmonary fibrosis (IPF) is still unknown. Some experts would like to reclassify this disease. What classification options are available? What would a focus on the "progressive…
Brigatinib in the Therapy of ALK-Positive NSCLC in Patients Refractory to Crizotinib Therapy – Results of the Final Analysis of Clinical Studies
Previously published results of clinical studies have shown that in patients refractory to crizotinib therapy, the administration of brigatinib led to a high rate of therapeutic response (systemic…
Brigatinib in the Therapy of ALK-Positive NSCLC – First Results of the J-ALTA Study
Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor with broad and potent activity against ALK gene mutations causing resistance to ALK inhibitor therapy (ALKi). In patients refractory to…
Ivabradine and/or Sacubitril/Valsartan in the Treatment of Heart Failure with Reduced Ejection Fraction
Ivabradine and sacubitril/valsartan are used in the second line of therapy for heart failure with reduced ejection fraction (HFrEF). The aim of the study presented below was to evaluate the…
Variability of COPD Symptoms During the Day and Impact on Patients' Morning Routine – Survey Results
Chronic obstructive pulmonary disease (COPD) is viewed, unlike bronchial asthma, as a condition with a more chronic course and less variability of symptoms throughout the day. The study presented…
Atectura® and Enerzair® from May 1, 2021 with Health Insurance Coverage
The fixed combination of indacaterol acetate (LABA) and mometasone furoate (ICS) Atectura® and the fixed triple combination, which in addition to these two substances also includes glycopyrronium…
New Strategies in the Treatment of Schizophrenia
Schizophrenia was primarily associated with dopamine dysfunction. Previous and current treatments have mainly targeted the mesolimbic dopamine pathway in the CNS and D2 receptors. However, the cited…
Popular this week
- Imunoglukan P4H® in the Prevention of Recurrent Respiratory Infections in Childhood
- BENIGN DERMATOSIS OF PENIS
- Fractures of the fifth metatarsal base
- SPEECH AND LANGUAGE ASSESSMENT IN ADULT COCHLEAR IMPLANT CANDIDATES AND USERS
- Nystatin – Newly Available Drug for Extemporaneous Preparation